Ma Lianjun, Zhou Naikang, Qi Yanjun, Liu Huifeng, Zhao Yachao, Zheng Mengli
Department of Thoracic Surgery, Chinese PLA General Hospital, Beijing 100853, China;Department of Thoracic Surgery, Chinese PLA 309th Hospital, Beijing 100091, China.
Zhongguo Fei Ai Za Zhi. 2013 Dec;16(12):621-4. doi: 10.3779/j.issn.1009-3419.2013.12.01.
Residual carcinoma cells play an important role in the result of radiofrequency ablation (RFA) of pulmonary malignancies, and Platinum-based adjuvant chemotherapy is one of the important treatment regimen to reduce residual carcinoma cells after RFA. ERCC1 (excision repair cross-complementation group 1) is an important factor affecting Platinum-based chemotherapy effects. Residual carcinoma cells exhibit some changes of their features after RFA; however, there is no report about the change of their ERCC1 expression by now. This study focused on the change of ERCC1 expression in residual VX2 squamous carcinoma cells in rabbit lung after RFA.
The model of VX2 squamous carcinoma in rabbit lung was established by injection of tissue block suspension. Fifty-eight New Zealand White rabbits with VX2 squamous carcinoma were randomly divided into the control group (n=10) and the RFA group (n=48). During the RFA procedure in these models, residual carcinoma cells were achieved by controlling the range of electrode expanding, power output and treatment time. At different points of time, the positive rates of ERCC1 expression in residual carcinoma were detected by immunohistochemistry.
Comparing with the control group, the positive rate of ERCC1 expression in residual carcinoma in RFA group increases transiently within 1 d to 5 d (53.7% ± 1.6% & 32.9% ± 2.5%), and 5 d later, it decline to the level of the control group.
The ERCC1 expression of residual pulmonary carcinoma increase within 5 d after RFA. Thus platinum-based adjuvant chemotherapy may be ineffective in this period.
残留癌细胞在肺恶性肿瘤射频消融（RFA）结果中起重要作用，铂类辅助化疗是减少RFA后残留癌细胞的重要治疗方案之一。ERCC1（切除修复交叉互补组1）是影响铂类化疗效果的重要因素。残留癌细胞在RFA后其特征会发生一些变化；然而，目前尚无关于其ERCC1表达变化的报道。本研究聚焦于RFA后兔肺残留VX2鳞状癌细胞中ERCC1表达的变化。
通过注射组织块悬液建立兔肺VX2鳞状癌模型。58只患有VX2鳞状癌的新西兰白兔随机分为对照组（n = 10）和RFA组（n = 48）。在这些模型的RFA过程中，通过控制电极展开范围、功率输出和治疗时间获取残留癌细胞。在不同时间点，采用免疫组织化学法检测残留癌中ERCC1表达的阳性率。
与对照组相比，RFA组残留癌中ERCC1表达阳性率在1 d至5 d内短暂升高（53.7% ± 1.6% & 32.9% ± 2.5%），5 d后降至对照组水平。
RFA后5 d内残留肺癌的ERCC1表达升高。因此在此期间铂类辅助化疗可能无效。
